These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29018343)

  • 61. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
    Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
    Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
    Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
    Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.
    Jana K; Bandyopadhyay T; Ganguly B
    J Phys Chem B; 2016 Dec; 120(51):13031-13038. PubMed ID: 27992223
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
    J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
    Shirai N; Furuta T; Xiao F; Kajimura M; Hanai H; Ohashi K; Ishizaki T
    Aliment Pharmacol Ther; 2002 Apr; 16(4):837-46. PubMed ID: 11929404
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Characteristic features of proton pump inhibitors in the inhibition of gastric acid secretion: long-acting and complete inhibition].
    Ohe K
    Nihon Rinsho; 1992 Jan; 50(1):45-52. PubMed ID: 1311789
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
    Wang H; Nie YQ; Dai SJ; She QZ; Li YY
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):777-80. PubMed ID: 14636465
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The H+/K+ ATPase Inhibitor SCH-28080 Inhibits Insulin Secretion and Induces Cell Death in INS-1E Rat Insulinoma Cells.
    Jakab M; Ketterl N; Fürst J; Beyreis M; Kittl M; Kiesslich T; Hauser-Kronberger C; Gaisberger M; Ritter M
    Cell Physiol Biochem; 2017; 43(3):1037-1051. PubMed ID: 28968600
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics.
    Rodríguez-Alcolado L; Navarro P; Arias-González L; Grueso-Navarro E; Lucendo AJ; Laserna-Mendieta EJ
    Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675148
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps.
    Eken E; Estores DS; Cicali EJ; Wiisanen KK; Johnson JA
    Pharmgenomics Pers Med; 2023; 16():645-664. PubMed ID: 37383676
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways.
    Cheng Z; Liu Y; Ma M; Sun S; Ma Z; Wang Y; Yu L; Qian X; Sun L; Zhang X; Liu Y; Wang Y
    Mol Med; 2022 Feb; 28(1):21. PubMed ID: 35183103
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
    Lima JJ; Thomas CD; Barbarino J; Desta Z; Van Driest SL; El Rouby N; Johnson JA; Cavallari LH; Shakhnovich V; Thacker DL; Scott SA; Schwab M; Uppugunduri CRS; Formea CM; Franciosi JP; Sangkuhl K; Gaedigk A; Klein TE; Gammal RS; Furuta T
    Clin Pharmacol Ther; 2021 Jun; 109(6):1417-1423. PubMed ID: 32770672
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of Gastric
    Sun LN; Cao Y; Li YQ; Fang YQ; Zhang HW; Wang MF; Xie LJ; Chen J; Yang ZC; Bian ML; Li H; Zhang PP; Wei JF; Meng L; Zhang XH; Zhao P; Wang YQ
    Front Pharmacol; 2017; 8():670. PubMed ID: 29018343
    [No Abstract]   [Full Text] [Related]  

  • 76. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
    Wu L; Liu J; Zheng Y; Zhai Y; Lin M; Wu G; Lv D; Shentu J
    Clin Drug Investig; 2019 Oct; 39(10):953-965. PubMed ID: 31338800
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors.
    Zhang HJ; Zhang XH; Liu J; Sun LN; Shen YW; Zhou C; Zhang HW; Xie LJ; Chen J; Liu Y; Wang YQ
    Pharmacol Res; 2020 Feb; 152():104606. PubMed ID: 31846760
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
    Li YQ; Yan ZY; Zhang HW; Sun LN; Jiao HW; Wang MF; Yu LY; Yu L; Yuan ZQ; Meng L; Wang YQ
    Eur J Clin Pharmacol; 2017 May; 73(5):547-554. PubMed ID: 28138748
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.